[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346712-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346712-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multitarget-docking-and-molecular-enumeration-reveal-ddpmpypephu-as-a-potent-modulator-of-cell-cycle-glucocorticoid-and-estrogen-signalling-in-breast-cancer","Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer","","Breast cancer is one of the most prevalent cancers worldwide, ranked as the second most diagnosed cancer and the fourth leading cause of cancer-related deaths. Despite FDA-approved therapies, limitations such as drug resistance and off-target effects demand multitargeted alternatives. This study aimed to identify and design an in-silico multitarget drug by docking three key proteins—glucocorticoid receptor, ER-alpha, and CDK2—then enumerating top hits to generate 14,750 derivatives. Among them, DdpMPyPEPhU showed strong binding interactions, favorable docking/MM-GBSA and improved drug-like and pharmacokinetic profiles, with stability supported by DFT optimization, WaterMap, and 250 ns molecular dynamics.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multitarget-docking-and-molecular-enumeration-reveal-ddpmpypephu-as-a-potent-modulator-of-cell-cycle-glucocorticoid-and-estrogen-signalling-in-breast-cancer/346712/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multitarget-docking-and-molecular-enumeration-reveal-ddpmpypephu-as-a-potent-modulator-of-cell-cycle-glucocorticoid-and-estrogen-signalling-in-breast-cancer/346712.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the study?","Question",{"text":63,"@type":64},"To identify and design an in-silico multitarget therapeutic candidate for breast cancer by simultaneously targeting glucocorticoid receptor, ER-alpha, and CDK2 and optimizing promising ligands.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were candidate ligands selected and expanded?",{"text":68,"@type":64},"FDA-approved drugs for the three targets were first screened using multitarget molecular docking; the top 15 ligands were then subjected to molecular enumeration to generate 14,750 novel derivative compounds.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports DdpMPyPEPhU as a promising candidate?",{"text":72,"@type":64},"DdpMPyPEPhU showed strong stabilizing interactions in docking, favorable docking scores and MM-GBSA energies, and structural stability supported by DFT optimization, 5 ns WaterMap, and 250 ns molecular dynamics simulations, along with binding free energy calculations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346712,1790111820,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":113,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","OPEN ACCESS  \nCitation: Ahmad S, Qazi S, Bano N, Uddin R, Gautam PK, Raza K (2026) Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer. PLoS One 21(3): e0344028 .  \n[https://doi.org/10.1371/journal.pone.0344028](https://doi.org/10.1371/journal.pone.0344028)  \nEditor: Prashant Singh, Atma Ram Sanatan Dharma College University of Delhi, INDIA Received: December 5, 2025  \nAccepted: February 13, 2026  \nPublished: March 23, 2026  \nCopyright: © 2026 Ahmad et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: The datasets utilised in this research were obtained from publicly accessible databases, and a supplementary file is provided for the generated data during the analysis.  \nRESEARCH ARTICLE  \nMultitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer  \nShaban Ahmad1, Sahar Qazi1, Nagmi Bano1, Rahis Uddin2, Pramod Kumar Gautam3, Khalid Raza1*  \n1 Department of Computer Science, Jamia Millia Islamia, New Delhi, India, 2 Department of Chemistry, Jamia Millia Islamia, New Delhi, India, 3 Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India  \n* [kraza@jmi.ac.in](kraza@jmi.ac.in)  \nAbstract  \nBreast cancer is one of the most prevalent cancers worldwide, ranked as the second most diagnosed cancer and the fourth leading cause of cancer-related deaths. Despite the availability of FDA-approved therapies, limitations such as drug resistance and off-target effects highlight the need for novel, multitargeted therapeutic agents. In this study, we aimed to identify and design an in-silico promising multitarget drug for breast cancer by simultaneously targeting three critical proteins: Glucocorticoid Receptor, Estrogen Receptor-alpha (ER-alpha), and Cyclin-Dependent Kinase 2 (CDK2) . FDA-approved drugs corresponding to these targets were initially subjected to multitarget molecular docking to evaluate their binding affinities. Based on this screening, the 15 highest-ranking ligands were selected and underwent molecular enumeration, resulting in the generation of 14,750 novel derivative compounds. The re-docking identified 1-((R)-2,3-dihydroxypropyl) −3-(3-((R)-1–5-methyl- 1H-pyrrolo [2,3-b]pyridin-3-yl)ethyl)phenyl) urea (DdpMPyPEPhU) (Patent No. 202024101028.0) as a promising multitarget candidate. The compound exhibited enhanced binding pocket engagement through numerous stabilising interactions, including hydrogen bonds, π-π stacking, and π-cation interactions, with high docking scores (–14 .869 to –4.57 kcal/mol) and favourable Molecular Mechanics Generalised Born Surface Area (MM-GBSA) energies (–72 .32 to –11.97 kcal/mol) . Comparative docking and pharmacokinetic analyses with standard drugs Lapatinib and Tamoxifen indicated better drug-like properties and pharmacokinetic advantages for DdpMPyPEPhU. Additional validation using Density Functional Theory (DFT) optimisation, 5 ns WaterMap analysis, and 250 ns molecular dynamics simulations under neutralised conditions confirmed structural stability and strong intermolecular interactions, supported by binding free energy calculations. Overall, our computational findings  \nPLOS One | [https://doi.org/10.1371/journal.pone.0344028](https://doi.org/10.1371/journal.pone.0344028) March 23, 2026 1 / 30  \nFunding: This research was funded by the Indian Council of Medical Research (ICMR), New Delhi, under the Small  \nExtramural Research Programme, Project ID: IIRPSG-2024-01-02406 . The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: The compound described ","cbCaicFOGSfaA0LT","https://ap.wps.com/l/cbCaicFOGSfaA0LT","pdf",2766039,"English","# Abstract\n# Funding\n# Competing interests\n# Abbreviations","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To identify and design an in-silico multitarget therapeutic candidate for breast cancer by simultaneously targeting glucocorticoid receptor, ER-alpha, and CDK2 and optimizing promising ligands.\"},{\"question\":\"How were candidate ligands selected and expanded?\",\"answer\":\"FDA-approved drugs for the three targets were first screened using multitarget molecular docking; the top 15 ligands were then subjected to molecular enumeration to generate 14,750 novel derivative compounds.\"},{\"question\":\"What evidence supports DdpMPyPEPhU as a promising candidate?\",\"answer\":\"DdpMPyPEPhU showed strong stabilizing interactions in docking, favorable docking scores and MM-GBSA energies, and structural stability supported by DFT optimization, 5 ns WaterMap, and 250 ns molecular dynamics simulations, along with binding free energy calculations.\"}]","Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer | PDF",1790062493,76,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83d605cf7a42e045050cdbf74f7be3e9.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d40551cbb91dfd0a552fe8bb4672a4f4.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/245aae1e4fad3d8aef468d69426f6aa0.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35b9f9827911ec0e3723f3d32dcc8239.webp",980,1268]